• Explore /
  • Poster
  • / Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.

Two-year follow-up of KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (Pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) in ZUMA-3.

Abstract Video & Slides Poster

Authors

null

Bijal D. Shah

Moffitt Cancer Center, Tampa, FL

Bijal D. Shah , Armin Ghobadi , Olalekan O. Oluwole , Aaron Logan , Nicolas Boissel , Ryan Daniel Cassaday , Edouard Forcade , Michael Russell Bishop , Max S. Topp , Dimitrios Tzachanis , Kristen M. O'Dwyer , Martha Lucia Arellano , Yi Lin , Maria R. Baer , Gary J. Schiller , Lang Zhou , Petra C. Schuberth , Sabina Adhikary , Behzad Kharabi Masouleh , Roch Houot

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant

Track

Hematologic Malignancies

Sub Track

Acute Leukemia

Clinical Trial Registration Number

NCT02614066

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 7010)

DOI

10.1200/JCO.2022.40.16_suppl.7010

Abstract #

7010

Poster Bd #

241

Abstract Disclosures

Similar Posters

First Author: Bijal D. Shah

First Author: Olalekan O. Oluwole

First Author: Karnav Modi

First Author: Jose Caetano Villasboas